This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
4cni
From Proteopedia
(Difference between revisions)
| Line 2: | Line 2: | ||
<StructureSection load='4cni' size='340' side='right' caption='[[4cni]], [[Resolution|resolution]] 2.20Å' scene=''> | <StructureSection load='4cni' size='340' side='right' caption='[[4cni]], [[Resolution|resolution]] 2.20Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>[[4cni]] is a 6 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4CNI OCA]. <br> | + | <table><tr><td colspan='2'>[[4cni]] is a 6 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4CNI OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4CNI FirstGlance]. <br> |
| - | </td></tr><tr><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene>, <scene name='pdbligand=TAM:TRIS(HYDROXYETHYL)AMINOMETHANE'>TAM</scene | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene>, <scene name='pdbligand=TAM:TRIS(HYDROXYETHYL)AMINOMETHANE'>TAM</scene></td></tr> |
| - | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4cni FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4cni OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4cni RCSB], [http://www.ebi.ac.uk/pdbsum/4cni PDBsum]</span></td></tr> | |
| - | <tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4cni FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4cni OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4cni RCSB], [http://www.ebi.ac.uk/pdbsum/4cni PDBsum]</span></td></tr> | + | </table> |
| - | <table> | + | |
== Disease == | == Disease == | ||
[[http://www.uniprot.org/uniprot/IL6_HUMAN IL6_HUMAN]] Genetic variations in IL6 are associated with susceptibility to rheumatoid arthritis systemic juvenile (RASJ) [MIM:[http://omim.org/entry/604302 604302]]. An inflammatory articular disorder with systemic-onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis. Note=A IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in HIV-infected men. | [[http://www.uniprot.org/uniprot/IL6_HUMAN IL6_HUMAN]] Genetic variations in IL6 are associated with susceptibility to rheumatoid arthritis systemic juvenile (RASJ) [MIM:[http://omim.org/entry/604302 604302]]. An inflammatory articular disorder with systemic-onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis. Note=A IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in HIV-infected men. | ||
| Line 17: | Line 16: | ||
Discovery and characterization of olokizumab: A humanized antibody targeting interleukin-6 and neutralizing gp130-signaling.,Shaw S, Bourne T, Meier C, Carrington B, Gelinas R, Henry A, Popplewell A, Adams R, Baker T, Rapecki S, Marshall D, Moore A, Neale H, Lawson A MAbs. 2014 May 1;6(3):773-81. doi: 10.4161/mabs.28612. Epub 2014 Apr 2. PMID:24670876<ref>PMID:24670876</ref> | Discovery and characterization of olokizumab: A humanized antibody targeting interleukin-6 and neutralizing gp130-signaling.,Shaw S, Bourne T, Meier C, Carrington B, Gelinas R, Henry A, Popplewell A, Adams R, Baker T, Rapecki S, Marshall D, Moore A, Neale H, Lawson A MAbs. 2014 May 1;6(3):773-81. doi: 10.4161/mabs.28612. Epub 2014 Apr 2. PMID:24670876<ref>PMID:24670876</ref> | ||
| - | From | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> |
</div> | </div> | ||
== References == | == References == | ||
| Line 23: | Line 22: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
| - | [[Category: Adams, R | + | [[Category: Human]] |
| - | [[Category: Baker, T | + | [[Category: Adams, R]] |
| - | [[Category: Bourne, T | + | [[Category: Baker, T]] |
| - | [[Category: Carrington, B | + | [[Category: Bourne, T]] |
| - | [[Category: Gelinas, R | + | [[Category: Carrington, B]] |
| - | [[Category: Henry, A | + | [[Category: Gelinas, R]] |
| - | [[Category: Lawson, A | + | [[Category: Henry, A]] |
| - | [[Category: Marshall, D | + | [[Category: Lawson, A]] |
| - | [[Category: Meier, C | + | [[Category: Marshall, D]] |
| - | [[Category: Neale, H | + | [[Category: Meier, C]] |
| - | [[Category: Popplewell, A | + | [[Category: Neale, H]] |
| - | [[Category: Rapecki, S | + | [[Category: Popplewell, A]] |
| - | [[Category: Shaw, S | + | [[Category: Rapecki, S]] |
| + | [[Category: Shaw, S]] | ||
[[Category: Cdp6038]] | [[Category: Cdp6038]] | ||
[[Category: Immune system]] | [[Category: Immune system]] | ||
[[Category: Interleukin 6]] | [[Category: Interleukin 6]] | ||
Revision as of 12:20, 4 January 2015
Crystal structure of the Fab portion of Olokizumab in complex with IL- 6
| |||||||||||
Categories: Human | Adams, R | Baker, T | Bourne, T | Carrington, B | Gelinas, R | Henry, A | Lawson, A | Marshall, D | Meier, C | Neale, H | Popplewell, A | Rapecki, S | Shaw, S | Cdp6038 | Immune system | Interleukin 6
